^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MEF2C overexpression

    i
    Other names: MEF2C, Myocyte Enhancer Factor 2C, Myocyte-Specific Enhancer Factor 2C, MADS Box Transcription Enhancer Factor 2, Polypeptide C
    Entrez ID:
    4208
    8ms
    Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements. (PubMed, Ann Hematol)
    In conclusion, EVI1 & MEF2C were significantly expressed in AML cases. EVI1 & MEF2C overexpression were significantly associated with 11q23 rearrangements and t (9;22) and were indicators for poor outcome in adult AML patients; These results could be a step towards personalized therapy in those patients.
    Journal
    |
    MECOM (MDS1 And EVI1 Complex Locus) • MEF2C (Myocyte Enhancer Factor 2C)
    |
    MEF2C overexpression
    2years
    CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77. (PubMed, Bioorg Chem)
    Since CC1007 demonstrates remarkable anti-MM effect on MM cells, it may be a promising drug for the treatment of MM.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • SDC1 (Syndecan 1) • MEF2C (Myocyte Enhancer Factor 2C)
    |
    MEF2C overexpression
    over2years
    Hypermethylation of tumor suppressor lncRNA MEF2C-AS1 frequently happened in patients at all stages of colorectal carcinogenesis. (PubMed, Clin Epigenetics)
    The findings reveal that MEF2C-AS1 hypermethylation might be an early driven event during colorectal carcinogenesis. It might serve as a promising prognostic biomarker for CRC survival. Our study also indicates the potential tumor-suppressing role of MEF2C-AS1 in CRC.
    Journal
    |
    MEF2C (Myocyte Enhancer Factor 2C)
    |
    MEF2C overexpression
    3years
    Manipulating MEF2C: Discovering Novel Drugs to Target ETP-ALL (ASH 2021)
    Together, these data show that MEF2C is an oncogenic driver of ETP-ALL, and ectopic expression of MEF2C negatively affects steroid sensitivity. Specific targeting of only those HDACs that promote MEF2C activity may provide new therapeutic options in ETP-ALL by inhibiting MEF2C function and enhancing steroid sensitivity.
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • LMO2 (LIM Domain Only 2) • MEF2C (Myocyte Enhancer Factor 2C)
    |
    BCL2 expression • MEF2C overexpression